98 results on '"Pallansch, Mark A."'
Search Results
2. Coordinated global cessation of oral poliovirus vaccine use: Options and potential consequences.
- Author
-
Kalkowska, Dominika A., Wassilak, Steven G. F., Wiesen, Eric, Burns, Cara C., Pallansch, Mark A., Badizadegan, Kamran, and Thompson, Kimberly M.
- Abstract
Due to the very low, but nonzero, paralysis risks associated with the use of oral poliovirus vaccine (OPV), eradicating poliomyelitis requires ending all OPV use globally. The Global Polio Eradication Initiative (GPEI) coordinated cessation of Sabin type 2 OPV (OPV2 cessation) in 2016, except for emergency outbreak response. However, as of early 2023, plans for cessation of bivalent OPV (bOPV, containing types 1 and 3 OPV) remain undefined, and OPV2 use for outbreak response continues due to ongoing transmission of type 2 polioviruses and reported type 2 cases. Recent development and use of a genetically stabilized novel type 2 OPV (nOPV2) leads to additional potential vaccine options and increasing complexity in strategies for the polio endgame. Prior applications of integrated global risk, economic, and poliovirus transmission modeling consistent with GPEI strategic plans that preceded OPV2 cessation explored OPV cessation dynamics and the evaluation of options to support globally coordinated risk management efforts. The 2022–2026 GPEI strategic plan highlighted the need for early bOPV cessation planning. We review the published modeling and explore bOPV cessation immunization options as of 2022, assuming that the GPEI partners will not support restart of the use of any OPV type in routine immunization after a globally coordinated cessation of such use. We model the potential consequences of globally coordinating bOPV cessation in 2027, as anticipated in the 2022–2026 GPEI strategic plan. We do not find any options for bOPV cessation likely to succeed without a strategy of bOPV intensification to increase population immunity prior to cessation. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Worst‐case scenarios: Modeling uncontrolled type 2 polio transmission.
- Author
-
Kalkowska, Dominika A., Wiesen, Eric, Wassilak, Steven G. F., Burns, Cara C., Pallansch, Mark A., Badizadegan, Kamran, and Thompson, Kimberly M.
- Abstract
In May 2016, the Global Polio Eradication Initiative (GPEI) coordinated the cessation of all use of type 2 oral poliovirus vaccine (OPV2), except for emergency outbreak response. Since then, paralytic polio cases caused by type 2 vaccine‐derived polioviruses now exceed 3,000 cases reported by 39 countries. In 2022 (as of April 25, 2023), 20 countries reported detection of cases and nine other countries reported environmental surveillance detection, but no reported cases. Recent development of a genetically modified novel type 2 OPV (nOPV2) may help curb the generation of neurovirulent vaccine‐derived strains; its use since 2021 under Emergency Use Listing is limited to outbreak response activities. Prior modeling studies showed that the expected trajectory for global type 2 viruses does not appear headed toward eradication, even with the best possible properties of nOPV2 assuming current outbreak response performance. Continued persistence of type 2 poliovirus transmission exposes the world to the risks of potentially high‐consequence events such as the importation of virus into high‐transmission areas of India or Bangladesh. Building on prior polio endgame modeling and assuming current national and GPEI outbreak response performance, we show no probability of successfully eradicating type 2 polioviruses in the near term regardless of vaccine choice. We also demonstrate the possible worst‐case scenarios could result in rapid expansion of paralytic cases and preclude the goal of permanently ending all cases of poliomyelitis in the foreseeable future. Avoiding such catastrophic scenarios will depend on the development of strategies that raise population immunity to type 2 polioviruses. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Outbreak of Poliomyelitis in Hispaniola Associated with Circulating Type 1 Vaccine-Derived Poliovirus
- Author
-
Kew, Olen, Morris-Glasgow, Victoria, Landaverde, Mauricio, Burns, Cara, Shaw, Jing, Garib, Zacarias, André, Jean, Blackman, Elizabeth, Freeman, C. Jason, Jorba, Jaume, Sutter, Roland, Tambini, Gina, Venczel, Linda, Pedreira, Cristina, Laender, Fernando, Shimizu, Hiroyuki, Yoneyama, Tetsuo, Miyamura, Tatsuo, van der Avoort, Harrie, Oberste, M. Steven, Kilpatrick, David, Cochi, Stephen, Pallansch, Mark, and de Quadros, Ciro
- Published
- 2002
5. Insights from a Systematic Search for Information on Designs, Costs, and Effectiveness of Poliovirus Environmental Surveillance Systems
- Author
-
Duintjer Tebbens, Radboud J., Zimmermann, Marita, Pallansch, Mark A., and Thompson, Kimberly M.
- Published
- 2017
- Full Text
- View/download PDF
6. Interim CDC Guidance for Polio Vaccination for Travel to and from Countries Affected by Wild Poliovirus
- Author
-
Wallace, Gregory S., Seward, Jane F., and Pallansch, Mark A.
- Published
- 2014
7. Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response.
- Author
-
Kalkowska, Dominika A., Pallansch, Mark A., Wassilak, Steven G.F., Cochi, Stephen L., and Thompson, Kimberly M.
- Subjects
- *
ORAL vaccines , *POLIOVIRUS , *VIRAL transmission , *DISEASE outbreaks , *COVID-19 pandemic , *POLIO - Abstract
The Global Polio Eradication Initiative (GPEI) faces substantial challenges with managing outbreaks of serotype 2 circulating vaccine-derived polioviruses (cVDPV2s) in 2021. A full five years after the globally coordinated removal of serotype 2 oral poliovirus vaccine (OPV2) from trivalent oral poliovirus vaccine (tOPV) for use in national immunization programs, cVDPV2s did not die out. Since OPV2 cessation, responses to outbreaks caused by cVDPV2s mainly used serotype 2 monovalent OPV (mOPV2) from a stockpile. A novel vaccine developed from a genetically stabilized OPV2 strain (nOPV2) promises to potentially facilitate outbreak response with lower prospective risks, although its availability and properties in the field remain uncertain. Using an established global poliovirus transmission model and building on a related analysis that characterized the impacts of disruptions in GPEI activities caused by the COVID-19 pandemic, we explore the implications of trade-offs associated with delaying outbreak response to avoid using mOPV2 by waiting for nOPV2 availability (or equivalently, delayed responses waiting for national validation of meeting the criteria for nOPV2 initial use). Consistent with prior modeling, responding as quickly as possible with available mOPV2 promises to reduce the expected burden of disease in the outbreak population and to reduce the chances for the outbreak virus to spread to other areas. Delaying cVDPV2 outbreak response (e.g., modeled as no response January-June 2021) to wait for nOPV2 can considerably increase the total expected cases (e.g., by as many as 1,300 cVDPV2 cases in the African region during 2021–2023) and increases the likelihood of triggering the need to restart widescale preventive use of an OPV2-containing vaccine in national immunization programs that use OPV. Countries should respond to any cVDPV2 outbreaks quickly with rounds that achieve high coverage using any available OPV2, and plan to use nOPV2, if needed, once it becomes widely available based on evidence that it is as effective but safer in populations than mOPV2. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. An Outbreak of Wild Poliovirus in the Republic of Congo, 2010–2011
- Author
-
Patel, Minal K., Konde, Mandy Kader, Didi-Ngossaki, Boris Hermann, Ndinga, Edouard, Yogolelo, Riziki, Salla, Mbaye, Shaba, Keith, Everts, Johannes, Armstrong, Gregory L., Daniels, Danni, Burns, Cara, Wassilak, Steve, Pallansch, Mark, and Kretsinger, Katrina
- Published
- 2012
- Full Text
- View/download PDF
9. Randomized Trial of Type 1 and Type 3 Oral Monovalent Poliovirus Vaccines in Newborns in Africa
- Author
-
Waggie, Zainab, Geldenhuys, Hennie, Sutter, Roland W., Jacks, Mariana, Mulenga, Humphrey, Mahomed, Hassan, De Koek, Marwou, Hanekom, Willem, Pallansch, Mark A., Kahn, Anna-Lea, Burton, Anthony H., Sreevatsava, Meghana, and Hussey, Gregory
- Published
- 2012
- Full Text
- View/download PDF
10. Trends in the Risk of U.S. Polio Outbreaks and Poliovirus Vaccine Availability for Response
- Author
-
Thompson, Kimberly M., Wallace, Gregory S., Tebbens, Radboud J. Duintjer, Smith, Philip J., Barskey, Albert E., Pallansch, Mark A., Gallagher, Kathleen M., Alexander, James P., Armstrong, Gregory L., Cochi, Stephen L., and Wassilak, Steven G. F.
- Published
- 2012
11. Poliomyelitis-Related Case-Fatality Ratio in India, 2002-2006
- Author
-
Doshi, Sucheta J., Sandhu, Hardeep S., Venczel, Linda V., Hymbaugh, Karen J., Deshpande, Jagadish M., Pallansch, Mark A., Bahl, Sunil, Wenger, Jay D., and Cochi, Steve L.
- Published
- 2011
- Full Text
- View/download PDF
12. Transmission of Imported Vaccine-Derived Poliovirus in an Undervaccinated Community in Minnesota
- Author
-
Alexander, James P., Ehresmann, Kristen, Seward, Jane, Wax, Gary, Harriman, Kathleen, Fuller, Susan, Cebelinski, Elizabeth A., Chen, Qi, Jorba, Jaume, Kew, Olen M., Pallansch, Mark A., Oberste, M. Steven, Schleiss, Mark, Davis, Jeffrey P., Warshawsky, Bryna, Squires, Susan, and Hull, Harry F.
- Published
- 2009
- Full Text
- View/download PDF
13. A Large Vaccine-Derived Poliovirus Outbreak on Madura Island: Indonesia, 2005
- Author
-
Estívariz, Concepción F., Watkins, Margaret A., Handoko, Darmawali, Rusipah, Rusipah, Deshpande, Jagadish, Rana, Bardan J., Irawan, Eveline, Widhiastuti, Dyah, Pallansch, Mark A., Thapa, Arun, and Imari, Sholah
- Published
- 2008
- Full Text
- View/download PDF
14. Serologic Response to Inactivated Poliovirus Vaccine: A Randomized Clinical Trial Comparing 2 Vaccination Schedules in Puerto Rico
- Author
-
Dayan, Gustavo H., Thorley, Margaret, Rodríguez, Nayra, McLaughlin, Steve, Torres, Lourdes M., Seda, Antonio, Carbia, Marcia, Alexander, Lorraine N., Caceres, Victor, and Pallansch, Mark A.
- Published
- 2007
15. Poliovirus Vaccine Shedding among Persons with HIV in Abidjan, Cote d'Ivoire
- Author
-
Hennessey, Karen A., Lago, Hugues, Diomande, Fabien, Akoua-Koffi, Chantal, Caceres, Victor M., Pallansch, Mark A., Kew, Olen M., Nolan, Monica, and Zuber, Patrick L. F.
- Published
- 2005
16. Cell-Free Synthesis and Processing of the Proteins of Poliovirus
- Author
-
Shih, Ding S., Shih, C. T., Kew, Olen, Pallansch, Mark, Rueckert, Roland, and Kaesberg, Paul
- Published
- 1978
17. Sequential Use of Inactivated Poliovirus Vaccine followed by Oral Poliovirus Vaccine in Oman
- Author
-
Sutter, Roland W., Suleiman, Ali Jaffer M., Malankar, Pradeep G., Mehta, Firdosi R., Medany, Mahmud A., Arif, Mohammed Amir M., Linkins, Robert W., Pallansch, Mark A., EI-Bualy, Mussalam S., and Robertson, Susan E.
- Published
- 1997
18. Increased Immunogenicity of Oral Poliovirus Vaccine Administered in Mass Vaccination Campaigns Compared with the Routine Vaccination Program in Jordan
- Author
-
Reichler, Mary R., Kharabsheh, Sa'ad, Rhodes, Philip, Otoum, Haider, Bloch, Samir, Majid, Mazen Abdel, Pallansch, Mark A., Patriarca, Peter A., and Cochi, Stephen L.
- Published
- 1997
19. Outbreak of Poliomyelitis in Gizan, Saudi Arabia: Cocirculation of Wild Type 1 Polioviruses from Three Separate Origins
- Author
-
Afif, Huda, Sutter, Roland W., Kew, Olen M., Fontaine, Robert E., Pallansch, Mark A., Goyal, Mahesh K., and Cochi, Stephen L.
- Published
- 1997
20. A Theoretical Framework for Evaluating the Sensitivity of Surveillance for Detecting Wild Polio virus: II. Factors Affecting Detection Sensitivity in a Population with Circulating Wild Poliovirus
- Author
-
Gary, Howard E., Sanders, Ray, and Pallansch, Mark A.
- Published
- 1997
21. A Theoretical Framework for Evaluating the Sensitivity of Surveillance for Detecting Wild Poliovirus: I. Factors Affecting Detection Sensitivity in a Person with Acute Flaccid Paralysis
- Author
-
Gary, Howard E., Sanders, Ray, and Pallansch, Mark A.
- Published
- 1997
22. Updated Characterization of Poliovirus Transmission in Pakistan and Afghanistan and the Impacts of Different Outbreak Response Vaccine Options.
- Author
-
Kalkowska, Dominika A, Pallansch, Mark A, Cochi, Stephen L, and Thompson, Kimberly M
- Subjects
- *
COVID-19 , *VACCINE effectiveness , *POLIOVIRUS , *COVID-19 pandemic , *HERD immunity - Abstract
Background: Pakistan and Afghanistan remain the only reservoirs of wild poliovirus transmission. Prior modeling suggested that before the coronavirus disease 2019 (COVID-19) pandemic, plans to stop the transmission of serotype 1 wild poliovirus (WPV1) and persistent serotype 2 circulating vaccine-derived poliovirus (cVDPV2) did not appear on track to succeed.Methods: We updated an existing poliovirus transmission and Sabin-strain oral poliovirus vaccine (OPV) evolution model for Pakistan and Afghanistan to characterize the impacts of immunization disruptions and restrictions on human interactions (ie, population mixing) due to the COVID-19 pandemic. We also consider different options for responding to outbreaks and for preventive supplementary immunization activities (SIAs).Results: The modeling suggests that with some resumption of activities in the fall of 2020 to respond to cVDPV2 outbreaks and full resumption on 1 January 2021 of all polio immunization activities to pre-COVID-19 levels, Pakistan and Afghanistan would remain off-track for stopping all transmission through 2023 without improvements in quality.Conclusions: Using trivalent OPV (tOPV) for SIAs instead of serotype 2 monovalent OPV offers substantial benefits for ending the transmission of both WPV1 and cVDPV2, because tOPV increases population immunity for both serotypes 1 and 2 while requiring fewer SIA rounds, when effectively delivered in transmission areas. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
23. Modeling Poliovirus Surveillance and Immunization Campaign Quality Monitoring Costs for Pakistan and Afghanistan for 2019–2023.
- Author
-
Kalkowska, Dominika A, Pallansch, Mark A, Cochi, Stephen L, and Thompson, Kimberly M
- Subjects
- *
POLIOVIRUS , *ACUTE flaccid paralysis , *IMMUNIZATION , *WATERSHEDS , *PUBLIC service advertising - Abstract
Background The Global Polio Eradication Initiative (GPEI) Strategic Plan for 2019–2023 includes commitments to monitor the quality of immunization campaigns using lot quality assurance sampling surveys (LQAS) and to support poliovirus surveillance in Pakistan and Afghanistan. Methods We analyzed LQAS and poliovirus surveillance data between 2016 and 2020, which included both acute flaccid paralysis (AFP) case-based detection and the continued expansion of environmental surveillance (ES). Using updated estimates for unit costs, we explore the costs of different options for future poliovirus monitoring and surveillance for Pakistan and Afghanistan. Results The relative value of the information provided by campaign quality monitoring and surveillance remains uncertain and depends on the design, implementation, and performance of the systems. Prospective immunization campaign quality monitoring (through LQAS) and poliovirus surveillance will require tens of millions of dollars each year for the foreseeable future for Pakistan and Afghanistan. Conclusions LQAS campaign monitoring as currently implemented in Pakistan and Afghanistan provides limited and potentially misleading information about immunization quality. AFP surveillance in Pakistan and Afghanistan provides the most reliable evidence of transmission, whereas ES provides valuable supplementary information about the extent of transmission in the catchment areas represented at the time of sample collection. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
24. Updated Characterization of Post‐OPV Cessation Risks: Lessons from 2019 Serotype 2 Outbreaks and Implications for the Probability of OPV Restart.
- Author
-
Kalkowska, Dominika A., Pallansch, Mark A., Cochi, Stephen L., Kovacs, Stephanie D., Wassilak, Steven G. F., and Thompson, Kimberly M.
- Subjects
ORAL vaccines ,PROBABILITY theory ,EMERGENCY management ,POLIO ,POLIOVIRUS - Abstract
After the globally coordinated cessation of any serotype of oral poliovirus vaccine (OPV), some risks remain from undetected, existing homotypic OPV‐related transmission and/or restarting transmission due to several possible reintroduction risks. The Global Polio Eradication Initiative (GPEI) coordinated global cessation of serotype 2‐containing OPV (OPV2) in 2016. Following OPV2 cessation, the GPEI and countries implemented activities to withdraw all the remaining trivalent OPV, which contains all three poliovirus serotypes (i.e., 1, 2, and 3), from the supply chain and replace it with bivalent OPV (containing only serotypes 1 and 3). However, as of early 2020, monovalent OPV2 use for outbreak response continues in many countries. In addition, outbreaks observed in 2019 demonstrated evidence of different types of risks than previously modeled. We briefly review the 2019 epidemiological experience with serotype 2 live poliovirus outbreaks and propose a new risk for unexpected OPV introduction for inclusion in global modeling of OPV cessation. Using an updated model of global poliovirus transmission and OPV evolution with and without consideration of this new risk, we explore the implications of the current global situation with respect to the likely need to restart preventive use of OPV2 in OPV‐using countries. Simulation results without this new risk suggest OPV2 restart will likely need to occur (81% of 100 iterations) to manage the polio endgame based on the GPEI performance to date with existing vaccine tools, and with the new risk of unexpected OPV introduction the expected OPV2 restart probability increases to 89%. Contingency planning requires new OPV2 bulk production, including genetically stabilized OPV2 strains. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
25. Global Transmission of Live Polioviruses: Updated Dynamic Modeling of the Polio Endgame.
- Author
-
Kalkowska, Dominika A., Pallansch, Mark A., Wassilak, Steven G. F., Cochi, Stephen L., and Thompson, Kimberly M.
- Subjects
POLIO ,DYNAMIC models ,ORAL vaccines ,POLIOVIRUS ,STOCHASTIC models - Abstract
Nearly 20 years after the year 2000 target for global wild poliovirus (WPV) eradication, live polioviruses continue to circulate with all three serotypes posing challenges for the polio endgame. We updated a global differential equation‐based poliovirus transmission and stochastic risk model to include programmatic and epidemiological experience through January 2020. We used the model to explore the likely dynamics of poliovirus transmission for 2019–2023, which coincides with a new Global Polio Eradication Initiative Strategic Plan. The model stratifies the global population into 72 blocks, each containing 10 subpopulations of approximately 10.7 million people. Exported viruses go into subpopulations within the same block and within groups of blocks that represent large preferentially mixing geographical areas (e.g., continents). We assign representative World Bank income levels to the blocks along with polio immunization and transmission assumptions, which capture some of the heterogeneity across countries while still focusing on global poliovirus transmission dynamics. We also updated estimates of reintroduction risks using available evidence. The updated model characterizes transmission dynamics and resulting polio cases consistent with the evidence through 2019. Based on recent epidemiological experience and prospective immunization assumptions for the 2019–2023 Strategic Plan, the updated model does not show successful eradication of serotype 1 WPV by 2023 or successful cessation of oral poliovirus vaccine serotype 2‐related viruses. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
26. Updated Characterization of Outbreak Response Strategies for 2019–2029: Impacts of Using a Novel Type 2 Oral Poliovirus Vaccine Strain.
- Author
-
Kalkowska, Dominika A., Pallansch, Mark A., Wilkinson, Amanda, Bandyopadhyay, Ananda S., Konopka‐Anstadt, Jennifer L., Burns, Cara C., Oberste, M. Steven, Wassilak, Steven G. F., Badizadegan, Kamran, and Thompson, Kimberly M.
- Subjects
ORAL vaccines ,POLIO ,POLIOVIRUS ,IMMUNIZATION ,UNCERTAINTY - Abstract
Delays in achieving the global eradication of wild poliovirus transmission continue to postpone subsequent cessation of all oral poliovirus vaccine (OPV) use. Countries must stop OPV use to end all cases of poliomyelitis, including vaccine‐associated paralytic polio (VAPP) and cases caused by vaccine‐derived polioviruses (VDPVs). The Global Polio Eradication Initiative (GPEI) coordinated global cessation of all type 2 OPV (OPV2) use in routine immunization in 2016 but did not successfully end the transmission of type 2 VDPVs (VDPV2s), and consequently continues to use type 2 OPV (OPV2) for outbreak response activities. Using an updated global poliovirus transmission and OPV evolution model, we characterize outbreak response options for 2019–2029 related to responding to VDPV2 outbreaks with a genetically stabilized novel OPV (nOPV2) strain or with the currently licensed monovalent OPV2 (mOPV2). Given uncertainties about the properties of nOPV2, we model different assumptions that appear consistent with the evidence on nOPV2 to date. Using nOPV2 to respond to detected cases may reduce the expected VDPV and VAPP cases and the risk of needing to restart OPV2 use in routine immunization compared to mOPV2 use for outbreak response. The actual properties, availability, and use of nOPV2 will determine its effects on type 2 poliovirus transmission in populations. Even with optimal nOPV2 performance, countries and the GPEI would still likely need to restart OPV2 use in routine immunization in OPV‐using countries if operational improvements in outbreak response to stop the transmission of cVDPV2s are not implemented effectively. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
27. Modeling Poliovirus Transmission in Borno and Yobe, Northeast Nigeria.
- Author
-
Kalkowska, Dominika A., Franka, Richard, Higgins, Jeff, Kovacs, Stephanie D., Forbi, Joseph C., Wassilak, Steven G. F., Pallansch, Mark A., and Thompson, Kimberly M.
- Subjects
POLIOVIRUS ,HEALTH service areas ,WATERSHEDS ,ORAL vaccines - Abstract
Beginning in 2013, multiple local government areas (LGAs) in Borno and Yobe in northeast Nigeria and other parts of the Lake Chad basin experienced a violent insurgency that resulted in substantial numbers of isolated and displaced people. Northeast Nigeria represents the last known reservoir country of wild poliovirus (WPV) transmission in Africa, with detection of paralytic cases caused by serotype 1 WPV in 2016 in Borno and serotype 3 WPV in late 2012. Parts of Borno and Yobe are also problematic areas for transmission of serotype 2 circulating vaccine‐derived polioviruses, and they continue to face challenges associated with conflict and inadequate health services in security‐compromised areas that limit both immunization and surveillance activities. We model poliovirus transmission of all three serotypes for Borno and Yobe using a deterministic differential equation‐based model that includes four subpopulations to account for limitations in access to immunization services and dynamic restrictions in population mixing. We find that accessibility issues and insufficient immunization allow for prolonged poliovirus transmission and potential undetected paralytic cases, although as of the end of 2019, including responsive program activities in the modeling suggest die out of indigenous serotypes 1 and 3 WPVs prior to 2020. Specifically, recent and current efforts to access isolated populations and provide oral poliovirus vaccine continue to reduce the risks of sustained and undetected transmission, although some uncertainty remains. Continued improvement in immunization and surveillance in the isolated subpopulations should minimize these risks. Stochastic modeling can build on this analysis to characterize the implications for undetected transmission and confidence about no circulation. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
28. Progress Toward Poliovirus Containment Implementation - Worldwide, 2019-2020.
- Author
-
Moffett, Daphne B., Llewellyn, Anna, Singh, Harpal, Saxentoff, Eugene, Partridge, Jeffrey, Boualam, Liliane, Pallansch, Mark, Wassilak, Steven, Asghar, Humayun, Roesel, Sigrun, Grabovac, Varja, Rey-Benito, Gloria, Barnor, Jacob, Theo, Andros, Swan, Joseph, Iakovenko, Maria, Baig, Najam, Gurung, Santosh, Pandel, Ekkehart, and Zaffran, Michel
- Subjects
POLIO ,POLIOVIRUS ,COVID-19 ,POLIOMYELITIS vaccines ,COVID-19 pandemic - Abstract
Since 1988, when World Health Organization (WHO) Member States and partners launched the Global Polio Eradication Initiative, the number of wild poliovirus (WPV) cases has declined from 350,000 in 125 countries to 176 in only two countries in 2019 (1). The Global Commission for the Certification of Poliomyelitis Eradication (GCC) declared two of the three WPV types, type 2 (WPV2) and type 3 (WPV3), eradicated globally in 2015 and 2019, respectively (1). Wild poliovirus type 1 (WPV1) remains endemic in Afghanistan and Pakistan (1). Containment under strict biorisk management measures is vital to prevent reintroduction of eradicated polioviruses into communities from poliovirus facilities. In 2015, Member States committed to contain type 2 polioviruses (PV2) in poliovirus-essential facilities (PEFs) certified in accordance with a global standard (2). Member states agreed to report national PV2 inventories annually, destroy unneeded PV2 materials, and, if retaining PV2 materials, establish national authorities for containment (NACs) and a PEF auditing process. Since declaration of WPV3 eradication in October 2019, these activities are also required with WPV3 materials. Despite challenges faced during 2019-2020, including the coronavirus disease 2019 (COVID-19) pandemic, the global poliovirus containment program continues to work toward important milestones. To maintain progress, all WHO Member States are urged to adhere to the agreed containment resolutions, including officially establishing legally empowered NACs and submission of PEF Certificates of Participation. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
29. The Global Polio Laboratory Network as a Platform for the Viral Vaccine-Preventable and Emerging Diseases Laboratory Networks.
- Author
-
Diop, Ousmane M., Kew, Olen M., de Gourville, Esther M., and Pallansch, Mark A.
- Subjects
POLIO ,QUALITY assurance ,MUSCLE hypotonia ,QUALITY assurance standards ,EMERGING infectious diseases ,THERAPEUTICS ,POLIO prevention ,VIRAL disease prevention ,LABORATORIES ,ORGANIZATIONAL change ,POLIOMYELITIS vaccines ,PUBLIC health surveillance ,RESEARCH funding ,VIRAL vaccines ,WORLD health - Abstract
The Global Polio Laboratory Network (GPLN) began building in the late 1980s on a 3-tiered structure of 146 laboratories with different and complementary technical and support capacities (poliovirus isolation, molecular strain characterization including sequencing, quality assurance, and research). The purpose of this network is to provide timely and accurate laboratory results to the Global Polio Eradication Initiative. Deeply integrated with field case-based surveillance, it ultimately provides molecular epidemiological data from polioviruses used to inform programmatic and immunization activities. This network of global coverage requires substantial investments in laboratory infrastructure, equipment, supplies, reagents, quality assurance, staffing and training, often in resource-limited settings. The GPLN has not only developed country capacities, but it also serves as a model to other global laboratory networks for vaccine-preventable diseases that will endure after the polio eradication goal is achieved. Leveraging lessons learned during past 27 years, the authors discuss options for transitioning GPLN assets to support control of other viral vaccine-preventable, emerging, and reemerging diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
30. Acute Flaccid Myelitis in the United States, August-December 2014: Results of Nationwide Surveillance.
- Author
-
Sejvar, James J., Lopez, Adriana S., Cortese, Margaret M., Leshem, Eyal, Pastula, Daniel M., Miller, Lisa, Glaser, Carol, Kambhampati, Anita, Kayoko Shioda, Aliabadi, Negar, Fischer, Marc, Gregoricus, Nicole, Lanciotti, Robert, Nix, W. Allan, Sakthivel, Senthilkumar K., Schmid, D. Scott, Seward, Jane F., Suxiang Tong, Oberste, M. Steven, and Pallansch, Mark
- Subjects
ACUTE flaccid paralysis ,MYELITIS ,ENTEROVIRUSES ,POLYMERASE chain reaction ,MUSCLE hypotonia ,PARALYSIS - Abstract
Background. During late summer/fall 2014, pediatric cases of acute flaccid myelitis (AFM) occurred in the United States, coincident with a national outbreak of enterovirus D68 (EV-D68)-associated severe respiratory illness. Methods. Clinicians and health departments reported standardized clinical, epidemiologic, and radiologic information on AFM cases to the Centers for Disease Control and Prevention (CDC), and submitted biological samples for testing. Cases were ≤21 years old, with acute onset of limb weakness 1 August-31 December 2014 and spinal magnetic resonance imaging (MRI) showing lesions predominantly restricted to gray matter. Results. From August through December 2014, 120 AFM cases were reported from 34 states. Median age was 7.1 years (interquartile range, 4.8-12.1 years); 59% were male. Most experienced respiratory (81%) or febrile (64%) illness before limb weakness onset. MRI abnormalities were predominantly in the cervical spinal cord (103/118). All but 1 case was hospitalized; none died. Cerebrospinal fluid (CSF) pleocytosis (>5 white blood cells/μL) was common (81%). At CDC, 1 CSF specimen was positive for EV-D68 and Epstein-Barr virus by real-time polymerase chain reaction, although the specimen had >3000 red blood cells/μL. The most common virus detected in upper respiratory tract specimens was EV-D68 (from 20%, and 47% with specimen collected ≤7 days from respiratory illness/fever onset). Continued surveillance in 2015 identified 16 AFM cases reported from 13 states. Conclusions. Epidemiologic data suggest this AFM cluster was likely associated with the large outbreak of EV-D68-associated respiratory illness, although direct laboratory evidence linking AFM with EV-D68 remains inconclusive. Continued surveillance will help define the incidence, epidemiology, and etiology of AFM. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
31. Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame.
- Author
-
Tebbens, Radboud J. Duintjer, Pallansch, Mark A., Wassilak, Steven G. F., Cochi, Stephen L., Thompson, Kimberly M., and Duintjer Tebbens, Radboud J
- Subjects
- *
POLIO prevention , *POLIOMYELITIS vaccines , *POLIOVIRUS genetics , *POLIO , *POLIO patients , *THERAPEUTICS , *PREVENTION of epidemics , *COMPARATIVE studies , *EMERGENCY management , *IMMUNIZATION , *INTERNATIONAL relations , *RESEARCH methodology , *MEDICAL cooperation , *RESEARCH , *RESEARCH funding , *RISK management in business , *EVALUATION research - Abstract
Background: Following successful eradication of wild polioviruses and planned globally-coordinated cessation of oral poliovirus vaccine (OPV), national and global health leaders may need to respond to outbreaks from reintroduced live polioviruses, particularly vaccine-derived polioviruses (VDPVs). Preparing outbreak response plans and assessing potential vaccine needs from an emergency stockpile require consideration of the different national risks and conditions as they change with time after OPV cessation.Methods: We used an integrated global model to consider several key issues related to managing poliovirus risks and outbreak response, including the time interval during which monovalent OPV (mOPV) can be safely used following homotypic OPV cessation; the timing, quality, and quantity of rounds required to stop transmission; vaccine stockpile needs; and the impacts of vaccine choices and surveillance quality. We compare the base case scenario that assumes aggressive outbreak response and sufficient mOPV available from the stockpile for all outbreaks that occur in the model, with various scenarios that change the outbreak response strategies.Results: Outbreak response after OPV cessation will require careful management, with some circumstances expected to require more and/or higher quality rounds to stop transmission than others. For outbreaks involving serotype 2, using trivalent OPV instead of mOPV2 following cessation of OPV serotype 2 but before cessation of OPV serotypes 1 and 3 would represent a good option if logistically feasible. Using mOPV for outbreak response can start new outbreaks if exported outside the outbreak population into populations with decreasing population immunity to transmission after OPV cessation, but failure to contain outbreaks resulting in exportation of the outbreak poliovirus may represent a greater risk. The possibility of mOPV use generating new long-term poliovirus excretors represents a real concern. Using the base case outbreak response assumptions, we expect over 25% probability of a shortage of stockpiled filled mOPV vaccine, which could jeopardize the achievement of global polio eradication. For the long term, responding to any poliovirus reintroductions may require a global IPV stockpile. Despite the risks, our model suggests that good risk management and response strategies can successfully control most potential outbreaks after OPV cessation.Conclusions: Health leaders should carefully consider the numerous outbreak response choices that affect the probability of successfully managing poliovirus risks after OPV cessation. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
32. Ending Use of Oral Poliovirus Vaccine - A Difficult Move in the Polio Endgame.
- Author
-
Pallansch, Mark A.
- Subjects
- *
PREVENTION of epidemics , *POLIO prevention , *ENTEROVIRUSES , *IMMUNIZATION , *POLIO , *POLIOMYELITIS vaccines , *PUBLIC health surveillance , *WORLD health , *DISEASE eradication - Abstract
The article focuses on the challenges of the organization, World Health Assembly to make policy changes post the decision to end the use of oral polio vaccines (OPV), considering the successful efforts of poliovirus eradication. Topics discussed include outbreak of circulating vaccine-derived poliovirus (cVDPV) due to wild poliovirus (WPV), role of Global Polio Eradication Initiative (GPEI), and need for research on better surveillance tools and vaccines for complete eradication of the virus.
- Published
- 2018
- Full Text
- View/download PDF
33. An economic analysis of poliovirus risk management policy options for 2013-2052.
- Author
-
Duintjer Tebbens, Radboud J., Pallansch, Mark A., Cochi, Stephen L., Wassilak, Steven G. F., and Thompson, Kimberly M.
- Subjects
- *
IMMUNIZATION , *POLIO prevention , *PUBLIC health & economics , *RISK management in business , *ANTIVIRAL agents , *ENTEROVIRUSES , *EPIDEMICS , *IMMUNOLOGICAL deficiency syndromes , *LONGITUDINAL method , *POLIO , *POLIOMYELITIS vaccines , *RESEARCH funding , *SEROTYPES , *ECONOMICS , *VACCINES ,POLIO transmission - Abstract
Background: The Global Polio Eradication Initiative plans for coordinated cessation of oral poliovirus vaccine (OPV) after interrupting all wild poliovirus (WPV) transmission, but many questions remain related to long-term poliovirus risk management policies.Methods: We used an integrated dynamic poliovirus transmission and stochastic risk model to simulate possible futures and estimate the health and economic outcomes of maintaining the 2013 status quo of continued OPV use in most developing countries compared with OPV cessation policies with various assumptions about global inactivated poliovirus vaccine (IPV) adoption.Results: Continued OPV use after global WPV eradication leads to continued high costs and/or high cases. Global OPV cessation comes with a high probability of at least one outbreak, which aggressive outbreak response can successfully control in most instances. A low but non-zero probability exists of uncontrolled outbreaks following a poliovirus reintroduction long after OPV cessation in a population in which IPV-alone cannot prevent poliovirus transmission. We estimate global incremental net benefits during 2013-2052 of approximately $16 billion (US$2013) for OPV cessation with at least one IPV routine immunization dose in all countries until 2024 compared to continued OPV use, although significant uncertainty remains associated with the frequency of exportations between populations and the implementation of long term risk management policies.Conclusions: Global OPV cessation offers the possibility of large future health and economic benefits compared to continued OPV use. Long-term poliovirus risk management interventions matter (e.g., IPV use duration, outbreak response, containment, continued surveillance, stockpile size and contents, vaccine production site requirements, potential antiviral drugs, and potential safer vaccines) and require careful consideration. Risk management activities can help to ensure a low risk of uncontrolled outbreaks and preserve or further increase the positive net benefits of OPV cessation. Important uncertainties will require more research, including characterizing immunodeficient long-term poliovirus excretor risks, containment risks, and the kinetics of outbreaks and response in an unprecedented world without widespread live poliovirus exposure. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
34. Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs.
- Author
-
Duintjer Tebbens, Radboud J., Pallansch, Mark A., and Thompson, Kimberly M.
- Subjects
- *
IMMUNOLOGICAL deficiency syndrome complications , *POLIO prevention , *ANTIVIRAL agents , *ENTEROVIRUSES , *IMMUNOLOGICAL deficiency syndromes , *MATHEMATICAL models , *POLIO , *POLIOMYELITIS vaccines , *RESEARCH funding , *RISK management in business , *SURVIVAL analysis (Biometry) , *THEORY , *DISEASE prevalence - Abstract
Background: A small number of individuals with B-cell-related primary immunodeficiency diseases (PIDs) may exhibit long-term (prolonged or chronic) excretion of immunodeficiency-associated vaccine-derived polioviruses (iVDPVs) following infection with oral poliovirus vaccine (OPV). These individuals pose a risk of live poliovirus reintroduction into the population after global wild poliovirus eradication and subsequent OPV cessation. Treatment with polio antiviral drugs may potentially stop excretion in some of these individuals and thus may reduce the future population risk.Methods: We developed a discrete event simulation model to characterize the global prevalence of long-term iVDPV excretors based on the best available evidence. We explored the impact of different assumptions about the effectiveness of polio antiviral drugs and the fraction of long-term excretors identified and treated.Results: Due to the rarity of long-term iVDPV excretion and limited data on the survival of PID patients in developing countries, uncertainty remains about the current and future prevalence of long-term iVDPV excretors. While the model suggests only approximately 30 current excretors globally and a rapid decrease after OPV cessation, most of these excrete asymptomatically and remain undetected. The possibility that one or more PID patients may continue to excrete iVDPVs for several years after OPV cessation represents a risk for reintroduction of live polioviruses after OPV cessation, particularly for middle-income countries. With the effectiveness of a single polio antiviral drug possibly as low as 40% and no system in place to identify and treat asymptomatic excretors, the impact of passive use of a single polio antiviral drug to treat identified excretors appears limited. Higher drug effectiveness and active efforts to identify long-term excretors will dramatically increase the benefits of polio antiviral drugs.Conclusions: Efforts to develop a second polio antiviral compound to increase polio antiviral effectiveness and/or to maximize the identification and treatment of affected individuals represent important risk management opportunities for the polio endgame. Better data on the survival of PID patients in developing countries and more longitudinal data on their exposure to and recovery from OPV infections would improve our understanding of the risks associated with iVDPV excretors and the benefits of further investments in polio antiviral drugs. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
35. Modeling options to manage type 1 wild poliovirus imported into Israel in 2013.
- Author
-
Kalkowska, Dominika A, Duintjer Tebbens, Radboud J, Grotto, Itamar, Shulman, Lester M, Anis, Emilia, Wassilak, Steven G F, Pallansch, Mark A, and Thompson, Kimberly M
- Abstract
Background: After 25 years without poliomyelitis cases caused by circulating wild poliovirus (WPV) in Israel, sewage sampling detected WPV type 1 (WPV1) in April 2013, despite high vaccination coverage with only inactivated poliovirus vaccine (IPV) since 2005.Methods: We used a differential equation-based model to simulate the dynamics of poliovirus transmission and population immunity in Israel due to past exposure to WPV and use of oral poliovirus vaccine (OPV) in addition to IPV. We explored the influences of various immunization options to stop imported WPV1 circulation in Israel.Results: We successfully modeled the potential for WPVs to circulate without detected cases in Israel. Maintaining a sequential IPV/OPV schedule instead of switching to an IPV-only schedule in 2005 would have kept population immunity high enough in Israel to prevent WPV1 circulation. The Israeli response to WPV1 detection prevented paralytic cases; a more rapid response might have interrupted transmission more quickly.Conclusions: IPV-based protection alone might not provide sufficient population immunity to prevent poliovirus transmission after an importation. As countries transition to IPV in immunization schedules, they may need to actively manage population immunity and consider continued use of OPV, to avoid the potential circulation of imported live polioviruses before globally coordinated cessation of OPV use. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
36. Polio Eradicators Use Integrated Analytical Models to Make Better Decisions.
- Author
-
Thompson, Kimberly M., Duintjer Tebbens, Radboud J., Pallansch, Mark A., Wassilak, Steven G. F., and Cochi, Stephen L.
- Subjects
POLIO prevention ,VIRAL transmission ,WORLD health ,HEALTH programs ,INTERNATIONAL cooperation ,PREVENTION - Abstract
Achieving global polio eradication requires that global stakeholders coordinate and cooperate to invest human and financial resources in interventions that prevent virus transmission. Reaching this goal depends on effective tools and interventions, and their optimal use. Poliovirus transmission occurs in a complex global system with rapidly evolving viruses that readily cross international borders. The U.S. Centers for Disease Control and Prevention, one of four spearheading partners of the Global Polio Eradication Initiative (GPEI), initiated a collaboration with Kid Risk, Inc. to develop and apply integrated analytical models to answer high-stakes policy questions related to managing the risks of polioviruses with consideration of human health and economic outcomes. Over the last decade, the collaboration innovatively combined numerous operations research and management science tools, including simulation, decision and risk analysis, system dynamics, and optimization to help policy makers understand and quantify the implications of their choices. These integrated modeling efforts helped motivate faster responses to polio outbreaks, leading to a global resolution and significantly reduced response time and outbreak sizes. Insights from the models also underpinned a 192-country resolution to coordinate global cessation of the use of one of the two vaccines after wild poliovirus eradication (i.e., allowing continued use of the other vaccine as desired). Finally, the model results helped us to make the economic case for a continued commitment to polio eradication by quantifying the value of prevention and showing the health and economic outcomes associated with the alternatives. The work helped to raise the billions of dollars needed to support polio eradication. The investments will prevent devastating cases of polio and realize an estimated $40-$50 billion in net benefits by the countries covered by the GPEI, while protecting the significantly larger net benefits enjoyed by the countries that stopped wild poliovirus transmission without support of the GPEI. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
37. Outbreak response strategies with type 2-containing oral poliovirus vaccines.
- Author
-
Kalkowska, Dominika A., Wassilak, Steven G.F., Pallansch, Mark A., Burns, Cara C., Wiesen, Eric, Durry, Elias, Badizadegan, Kamran, and Thompson, Kimberly M.
- Subjects
- *
ORAL vaccines , *POLIO , *AGE groups , *POLIOVIRUS - Abstract
• Timeliness, scope, and quality of cVDPV2 outbreak response campaigns substantially impact global risks. • Countries and GPEI could stop cVDPV2 transmission with existing vaccines if they improve campaigns. • The properties of nOPV2 use in the field remain uncertain, and GPEI needs to manage expectations. Despite exhaustive and fully-financed plans to manage the risks of globally coordinated cessation of oral poliovirus vaccine (OPV) containing type 2 (OPV2) prior to 2016, as of 2022, extensive, continued transmission of circulating vaccine-derived polioviruses (cVDPVs) type 2 (cVDPV2) remains. Notably, cumulative cases caused by cVDPV2 since 2016 now exceed 2,500. Earlier analyses explored the implications of using different vaccine formulations to respond to cVDPV2 outbreaks and demonstrated how different properties of novel OPV2 (nOPV2) might affect its performance compared to Sabin monovalent OPV2 (mOPV2). These prior analyses used fixed assumptions for how outbreak response would occur, but outbreak response implementation can change. We update an existing global poliovirus transmission model to explore different options for responding with different vaccines and assumptions about scope, delays, immunization intensity, target age groups, and number of rounds. Our findings suggest that in order to successfully stop all cVDPV2 transmission globally, countries and the Global Polio Eradication Initiative need to address the deficiencies in emergency outbreak response policy and implementation. The polio program must urgently act to substantially reduce response time, target larger populations — particularly in high transmission areas — and achieve high coverage with improved access to under-vaccinated subpopulations. Given the limited supplies of nOPV2 at the present, using mOPV2 intensively immediately, followed by nOPV2 intensively if needed and when sufficient quantities become available, substantially increases the probability of ending cVDPV2 transmission globally. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
38. Global oral poliovirus vaccine stockpile management as an essential preparedness and response mechanism for type 2 poliovirus outbreaks following global oral poliovirus vaccine type 2 withdrawal.
- Author
-
Harutyunyan, Vachagan, Quddus, Arshad, Pallansch, Mark, Zipursky, Simona, Woods, David, Ottosen, Ann, Vertefeuille, John, and Lewis, Ian
- Subjects
- *
POLIOVIRUS , *ORAL vaccines , *POLIOMYELITIS vaccines , *PREPAREDNESS , *POLIO - Abstract
Following the global declaration of indigenous wild poliovirus type 2 eradication in 2015, the world switched to oral polio vaccine (OPV) that removed the type 2 component. This 'switch' included the widespread introduction of inactivated poliovirus vaccine and the creation of a stockpile of monovalent type 2 OPV (mOPV2) to respond to potential polio virus Type 2 (PV2) outbreaks and events. With subsequent detection of outbreaks of circulating vaccine-derived poliovirus type 2 (cVDPV2), it was necessary to use this stockpile for outbreak response. Not only were more outbreaks detected than anticipated in the first few years after the switch, but the number of supplemental immunization activities (SIAs) used to stop transmission was often high, and in many cases did not stop wider transmission. Use of mOPV type 2 led in some locations to the emergence of new outbreaks that required further use of the vaccine from the stockpile. In the following years, stockpile management became a critical element of the cVDPV2 outbreak response strategy and continued to evolve to include trivalent OPV and genetically stabilized 'novel OPV type 2' vaccines in the stockpile. An overview of this process and its evolution is presented to highlight several of these management challenges. The unpredictable vaccine demand, fixed production and procurement timelines, resource requirements, and multiple vaccine types contributes to the complexity of assuring appropriate vaccine availability for this critical programmatic need to stop outbreaks. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
39. The impact of disruptions caused by the COVID-19 pandemic on global polio eradication.
- Author
-
Kalkowska, Dominika A., Voorman, Arend, Pallansch, Mark A., Wassilak, Steven G.F., Cochi, Stephen L., Badizadegan, Kamran, and Thompson, Kimberly M.
- Subjects
- *
POLIO , *COVID-19 pandemic , *ORAL vaccines , *MEDICAL care - Abstract
• The COVID-19 pandemic disrupted polio immunization activities. • Response to COVID-19 included substantial reductions in people mixing and traveling. • Early resumption of polio immunization activities could mitigate the impacts on poliovirus transmission. In early 2020, the COVID-19 pandemic led to substantial disruptions in global activities. The disruptions also included intentional and unintentional reductions in health services, including immunization campaigns against the transmission of wild poliovirus (WPV) and persistent serotype 2 circulating vaccine-derived poliovirus (cVDPV2). Building on a recently updated global poliovirus transmission and Sabin-strain oral poliovirus vaccine (OPV) evolution model, we explored the implications of immunization disruption and restrictions of human interactions (i.e., population mixing) on the expected incidence of polio and on the resulting challenges faced by the Global Polio Eradication Initiative (GPEI). We demonstrate that with some resumption of activities in the fall of 2020 to respond to cVDPV2 outbreaks and full resumption on January 1, 2021 of all polio immunization activities to pre-COVID-19 levels, the GPEI could largely mitigate the impact of COVID-19 to the delays incurred. The relative importance of reduced mixing (leading to potentially decreased incidence) and reduced immunization (leading to potentially increased expected incidence) depends on the timing of the effects. Following resumption of immunization activities, the GPEI will likely face similar barriers to eradication of WPV and elimination of cVDPV2 as before COVID-19. The disruptions from the COVID-19 pandemic may further delay polio eradication due to indirect effects on vaccine and financial resources. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
40. Intestinal Immunity Is a Determinant of Clearance of Poliovirus After Oral Vaccination.
- Author
-
Wright, Peter F., Wieland-Alter, Wendy, Ilyushina, Natalia A., Hoen, Anne G., Arita, Minetaro, Boesch, Austin W., Ackerman, Margaret E., van der Avoort, Harrie, Steven Oberste, M., Pallansch, Mark A., Burton, Anthony H., Jaffar, Mohammad A., and Sutter, Roland W.
- Subjects
POLIOMYELITIS vaccines ,IMMUNIZATION ,IMMUNOGLOBULIN A ,VIRAL shedding ,BLOOD serum analysis ,EPITOPES - Abstract
Background. Response to challenge with live, attenuated, oral polio vaccine (OPV) is a measure of immunity induced by prior immunization.Methods. Using stool samples from a study from Oman in which an initial schedule of inactivated polio vaccine (IPV) was followed by an OPV type 1 challenge, we quantitated virus shed, sequenced capsid proteins of recovered virus, and developed assays for neutralization of poliovirus and mucosal immunoglobulin A (IgA) detection.Results. Neutralizing activity correlated with detection of polio-specific IgA in stool suspensions collected 7 days after OPV type 1 challenge. Both neutralization and IgA in stool were associated with cessation of virus shedding by day 7. Rapid development of an IgA response with cessation of shedding suggests that IPV primed for the early response to challenge. Correlation of neutralization activity and IgA detection provides evidence that polio-specific IgA intestinal antibody is a determinant of mucosal shedding/transmission and that IgA functions through neutralization of virus. In contrast, neither presence nor quantity of serum or intestinal antibody induced by IPV prior to challenge correlated with cessation of shedding.Conclusions. These assays provide an opportunity to study other immunization schedules to gain a broader understanding of the appearance and duration of a protective mucosal response to polio vaccination. [ABSTRACT FROM PUBLISHER]
- Published
- 2014
- Full Text
- View/download PDF
41. The potential impact of expanding target age groups for polio immunization campaigns.
- Author
-
Duintjer Tebbens, Radboud J., Kalkowska, Dominika A., Wassilak, Steven G. F., Pallansch, Mark A., Cochi, Stephen L., and Thompson, Kimberly M.
- Subjects
EPIDEMICS ,AGE groups ,IMMUNIZATION ,IMMUNITY ,POLIO prevention ,VACCINES ,INFECTIOUS disease transmission - Abstract
Background Global efforts to eradicate wild polioviruses (WPVs) continue to face challenges due to uninterrupted endemic WPV transmission in three countries and importation-related outbreaks into previously polio-free countries. We explore the potential role of including older children and adults in supplemental immunization activities (SIAs) to more rapidly increase population immunity and prevent or stop transmission. Methods We use a differential equation-based dynamic poliovirus transmission model to analyze the epidemiological impact and vaccine resource implications of expanding target age groups in SIAs. We explore the use of older age groups in SIAs for three situations: alternative responses to the 2010 outbreak in Tajikistan, retrospective examination of elimination in northern India, and prospective and retrospective strategies to accelerate elimination in endemic northwestern Nigeria. Our model recognizes the ability of individuals with waned mucosal immunity (i.e., immunity from a historical live poliovirus infection) to become reinfected and contribute to transmission to a limited extent. Results SIAs involving expanded age groups reduce overall caseloads, decrease transmission, and generally lead to a small reduction in the time to achieve WPV elimination. Analysis of preventive expanded age group SIAs in Tajikistan or prior to type-specific surges in incidence in northern India and northwest Nigeria showed the greatest potential benefits of expanded age groups. Analysis of expanded age group SIAs in outbreak situations or to accelerate the interruption of endemic transmission showed relatively less benefit, largely due to the circulation of WPV reaching individuals sooner or more effectively than the SIAs. The results for northern India and northwestern Nigeria depend strongly on how well SIAs involving expanded age groups reach relatively isolated subpopulations that sustain clusters of susceptible children, which we assume play a key role in persistent endemic WPV transmission in these areas. Conclusions This study suggests the need to carefully consider the epidemiological situation in the context of decisions to use expanded age group SIAs. Subpopulations of susceptible individuals may independently sustain transmission, which will reduce the overall benefits associated with using expanded age group SIAs to increase population immunity to a sufficiently high level to stop transmission and reduce the incidence of paralytic cases. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
42. Uncertainty and Sensitivity Analyses of a Decision Analytic Model for Posteradication Polio Risk Management.
- Author
-
Duintjer Tebbens, Radboud J., Pallansch, Mark A., Kew, Olen M., Sutter, Roland W., Bruce Aylward, R., Watkins, Margaret, Gary, Howard, Alexander, James, Jafari, Hamid, Cochi, Stephen L., and Thompson, Kimberly M.
- Subjects
DECISION making ,POLIO ,RISK management in business ,POLIOVIRUS ,IMMUNIZATION ,CENTRAL nervous system infections - Abstract
Decision analytic modeling of polio risk management policies after eradication may help inform decisionmakers about the quantitative tradeoffs implied by various options. Given the significant dynamic complexity and uncertainty involving posteradication decisions, this article aims to clarify the structure of a decision analytic model developed to help characterize the risks, costs, and benefits of various options for polio risk management after eradication of wild polioviruses and analyze the implications of different sources of uncertainty. We provide an influence diagram of the model with a description of each component, explore the impact of different assumptions about model inputs, and present probability distributions of model outputs. The results show that choices made about surveillance, response, and containment for different income groups and immunization policies play a major role in the expected final costs and polio cases. While the overall policy implications of the model remain robust to the variations of assumptions and input uncertainty we considered, the analyses suggest the need for policymakers to carefully consider tradeoffs and for further studies to address the most important knowledge gaps. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
43. Risks of Paralytic Disease Due to Wild or Vaccine-Derived Poliovirus After Eradication.
- Author
-
Tebbens, Radboud J. Duintjer, Pallansch, Mark A., Kew, Olen M., Cáceres, Victor M., Jafari, Hamid, Cochi, Stephen L., Sutter, Roland W., Aylward, R. Bruce, and Thompson, Kimberly M.
- Subjects
POLIOVIRUS ,POLIO ,POLIOMYELITIS vaccines ,POLIO prevention ,PARALYSIS ,VACCINATION - Abstract
After the global eradication of wild polioviruses, the risk of paralytic poliomyelitis from polioviruses will still exist and require active management. Possible reintroductions of poliovirus that can spread rapidly in unprotected populations present challenges to policymakers. For example, at least one outbreak will likely occur due to circulation of a neurovirulent vaccine-derived poliovirus after discontinuation of oral poliovirus vaccine and also could possibly result from the escape of poliovirus from a laboratory or vaccine production facility or from an intentional act. In addition, continued vaccination with oral poliovirus vaccines would result in the continued occurrence of vaccine-associated paralytic poliomyelitis. The likelihood and impacts of reintroductions in the form of poliomyelitis outbreaks depend on the policy decisions and on the size and characteristics of the vulnerable population, which change over time. A plan for managing these risks must begin with an attempt to characterize and quantify them as a function of time. This article attempts to comprehensively characterize the risks, synthesize the existing data available for modeling them, and present quantitative risk estimates that can provide a starting point for informing policy decisions. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
44. Development and Consideration of Global Policies for Managing the Future Risks of Poliovirus Outbreaks: Insights and Lessons Learned Through Modeling.
- Author
-
Thompson, Kimberly M., Duintjer Tebbens, Radboud J., Pallansch, Mark A., Kew, Olen M., Sutter, Roland W., Aylward, R. Bruce, Watkins, Margaret, Gary, Howard, Alexander, James P., Venczel, Linda, Johnson, Denise, Cáceres, Victor M., Sangrujee, Nalinee, Jafari, Hamid, and Cochi, Stephen L.
- Subjects
POLIOMYELITIS vaccines ,QUALITY of life ,RISK management in business ,POLIOVIRUS ,DISEASE outbreaks ,ORAL vaccines ,POLIO ,DECISION making - Abstract
The success of the Global Polio Eradication Initiative promises to bring large benefits, including sustained improvements in quality of life (i.e., cases of paralytic disease and deaths avoided) and costs saved from cessation of vaccination. Obtaining and maintaining these benefits requires that policymakers manage the transition from the current massive use of oral poliovirus vaccine (OPV) to a world without OPV and free of the risks of potential future reintroductions of live polioviruses. This article describes the analytical journey that began in 2001 with a retrospective case study on polio risk management and led to development of dynamic integrated risk, economic, and decision analysis tools to inform global policies for managing the risks of polio. This analytical journey has provided several key insights and lessons learned that will be useful to future analysts involved in similar complex decision-making processes. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
45. Evaluation of Response Scenarios to Potential Polio Outbreaks Using Mathematical Models.
- Author
-
Thompson, Kimberly M., Duintjer Tebbens, Radboud J., and Pallansch, Mark A.
- Subjects
POLIOMYELITIS vaccines ,POLIO ,DISEASE outbreaks ,INFECTIOUS disease transmission ,IMMUNIZATION ,VACCINES ,POLIOVIRUS - Abstract
Appropriate response to polio outbreaks represents an important prerequisite for achieving and maintaining global polio eradication. We use an existing dynamic disease transmission model to evaluate the impact of different aspects of immunization campaigns in response to polio outbreaks occurring in previously polio-free areas. This analysis yields several important insights about response strategies. We find that delay in response represents a crucial risk factor for occurrence of large outbreaks and we characterize the tradeoffs associated with delaying the initial response to achieve better population coverage. We also demonstrate that controlling most potential outbreaks will likely require at least three immunization rounds, although the impact of the optimal interval between rounds varies. Finally, long after oral poliovirus vaccine cessation the choice of target age groups during a response represents an important consideration. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
46. Global Surveillance and the Value of Information: The Case of the Global Polio Laboratory Network.
- Author
-
De Gourville, Esther, Duintjer Tebbens, Radboud J., Sangrujee, Nalinee, Pallansch, Mark A., and Thompson, Kimberly M.
- Subjects
POLIO ,MUSCLE hypotonia ,PARALYSIS ,POLIOVIRUS - Abstract
Effective control and eradication of diseases requires reliable information from surveillance activities, including laboratories, which typically incur real financial costs. This article presents data from a survey we conducted to estimate the costs of the Global Polio Laboratory Network (GPLN), which currently supports aggressive global surveillance for acute flaccid paralysis (AFP) to detect circulating polioviruses. The Global Polio Eradication Initiative (GPEI) of the World Health Organization (WHO) provides resources for some of the laboratory network costs, but the total cost of the network remains relatively poorly characterized given the limited documentation of national contributions. We surveyed network laboratories to quantify AFP surveillance support costs and provide data for cost estimates of potential posteradication surveillance policies related to the laboratories. We estimate that the GPLN currently requires millions (US$ 2002) in total support annually, and that half of the support for national and regional reference laboratories comes from external donors through the WHO or bilateral agreements and half from within nations that host those laboratories. The article also presents the framework for considering the value of information from this global surveillance network and suggests that the expected value of surveillance information from the GPLN currently exceeds its costs. We also provided important insights about how the value of information may change after successful eradication of wild polioviruses. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
47. A Dynamic Model of Poliomyelitis Outbreaks: Learning from the Past to Help Inform the Future.
- Author
-
Duintjer Tebbens, Radboud J., Pallansch, Mark A., Kew, Olen M., Cáceres, Victor M., Sutter, Roland W., and Thompson, Kimberly M.
- Subjects
POLIO ,POLIOVIRUS ,DISEASE outbreaks ,ORAL poliomyelitis vaccines ,IMMUNIZATION ,VACCINATION - Abstract
Policy-makers now face important questions regarding the tradeoffs among different strategies for managing poliomyelitis risks after they succeed with polio eradication. To estimate the potential consequences of reintroductions of polioviruses and the resulting outbreaks, the authors developed a dynamic disease transmission model that can simulate many aspects of outbreaks for different posteradication conditions. In this paper, the authors identify the issues related to prospective modeling of future outbreaks using such a model, including the reality that accurate prediction of conditions and associated model inputs prior to future outbreaks remains challenging. The authors explored the model's behavior in the context of three recent outbreaks resulting from importation of poliovirus into previously polio-free countries and found that the model reproduced reported data on the incidence of cases. The authors expect that this model can provide important insights into the dynamics of future potential poliomyelitis outbreaks and in this way serve as a useful tool for risk assessment. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
48. Vaccine Policy Changes and Epidemiology of Poliomyelitis in the United States.
- Author
-
Alexander, Lorraine Niño, Seward, Jane F., Santibanez, Tammy A., Pallansch, Mark A., Kew, Olen M., Prevots, D. Rebecca, Strebel, Peter M., Cono, Joanne, Wharton, Melinda, Orenstein, Walter A., and Sutter, Roland W.
- Subjects
PREVENTIVE medicine ,CENTRAL nervous system diseases ,POLIO ,VACCINATION ,IMMUNIZATION ,PUBLIC health - Abstract
Context The last case of poliomyelitis in the United States due to indigenously acquired wild poliovirus occurred in 1979; however, as a consequence of oral poliovirus vaccine (OPV) use that began in 1961, an average of 9 cases of vaccine-associated paralytic poliomyelitis (VAPP) were confirmed each year from 1961 through 1989. To reduce the VAPP burden, national vaccination policy changed in 1997 from reliance on OPV to options for a sequential schedule of inactivated poliovirus vaccine (IPV) followed by OPV. In 2000, an exclusive IPV schedule was adopted. Objective To review the epidemiology of paralytic poliomyelitis and document the association between the vaccine schedule changes and VAPP in the United States. Design and Setting Review of national surveillance data from 1990 through 2003 for cases of confirmed paralytic poliomyelitis. Main Outcome Measures Number of confirmed paralytic poliomyelitis cases, including VAPP, and ratio of VAPP cases to number of doses of OPV distributed that occurred before, during, and after implementation of policy changes. Results From 1990 through 1999, 61 cases of paralytic poliomyelitis were reported; 59 (97%) of these were VAPP (1 case per 2.9 million OPV doses distributed), 1 case was imported, and 1 case was indeterminate. Thirteen cases occurred during the 1997-1999 transitional policy period and were associated with the all-OPV schedule; none occurred with the IPV-OPV schedule. No cases occurred after the United States implemented the all-IPV policy in 2000. The last imported poliomyelitis case occurred in 1993 and the last case of VAPP occurred in 1999. Conclusion The change in polio vaccination policy from OPV to exclusive use of IPV was successfully implemented; this change led to the elimination of VAPP in the United States. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
49. Persistence of Vaccine-Derived Polioviruses among Immunodeficient Persons with Vaccine-Associated Paralytic Poliomyelitis.
- Author
-
Khetsuriani, Nino, Prevots, D. Rebecca, Quick, Linda, Elder, Melissa E., Pallansch, Mark, Kew, Olen, and Sutter, Roland W.
- Subjects
POLIOVIRUS ,ENTEROVIRUSES ,IMMUNODEFICIENCY ,POLIO ,COMMUNICABLE diseases - Abstract
Presents a study which estimated long-term poliovaccine virus persistence among immunodeficient patients with vaccine-associated paralytic poliomyelitis. Review of cases reported in the U.S. during 1975-1997; Virological testing; Partial genomic sequencing of available poliovirus isolates which showed considerable divergence from the prototype Sabin strain in all cases; Poliovirus persistence; Poliovirus reintroduction in developed countries; Use of the study in developing concluding strategies for the Global Poliomyelitis Eradication Program.
- Published
- 2003
- Full Text
- View/download PDF
50. Paralytic poliomyelitis in Oman: association between regional differences in attack rate and variations in antibody responses to oral poliovirus vaccine.
- Author
-
SUTTER, ROLAND W, PATRIARCA, PETER A, SULEIMAN, ALI JAFFER M, PALLANSCH, MARK A, ZELL, ELIZABETH R, MALANKAR, PRADEEP G, BROGAN, SHAUN, AL-GHASSANI, AHMED A K, EL-BUALY, MUSALLAM S, Sutter, R W, Patriarca, P A, Suleiman, A J, Pallansch, M A, Zell, E R, Malankar, P G, Brogan, S, al-Ghassani, A A, and el-Bualy, M S
- Subjects
POLIO prevention ,ENTEROVIRUSES ,EPIDEMICS ,EPIDEMIOLOGICAL research ,POLIO ,POLIOMYELITIS vaccines ,PUBLIC health surveillance ,VIRAL antibodies ,DISEASE prevalence ,ANTIBODY formation - Abstract
Variation in attack rates of paralytic disease by region during the 1988–1989 epidemic of type 1 poliomyelitis in Oman provided the stimulus to test the hypothesis that these observations were due to regional differences in the response of infants to trivalent oral poliovirus vaccine (OPV). Seroprevalence studies of 394 children born during the outbreak were conducted in six different regions of Oman and in two socioeconomic status (SES) groups in the capital city of Muscat; a seroconversion study was also carried out in 105 infants born after the outbreak. Seroprevalence rates by region after receipt of at least three doses of OPV ranged from 90% to 100% (median 94%) to poliovirus type 1, and from 86% to 100% (median 97%) to type 2, and from 47% to 79% [median 72%) to type 3, with the lowest rates observed in regions with the highest incidence of type 1 paralytic disease. In Muscat, seroprevalence rates were also significantly lower in low versus high SES groups (type 1: 84% versus 98%. respectively [ = 0.006]; type 3: 59% versus 86%. respectively [ = 0.001]). In the seroconversion study conducted after the outbreak, 89%. 100% and 50% of infants had detectable antibodies to types 1, 2, and 3, respectively, after four doses of OPV. Low responses to type 3 were also associated with the occurrence of sporadic cases of type 3 poliomyelitis in 1991, in spite of high rates of coverage with at least four doses of OPV (>96%) throughout the country. These findings demonstrate that antibody responses to OPV may vary widely within individual countries, and that a uniform strategy to deliver at least three doses in routine programmes may be insufficient to achieve elimination of wild poliovirus infection. [ABSTRACT FROM PUBLISHER]
- Published
- 1993
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.